Trevena, Inc. (NASDAQ: TRVN) has been reiterated with a ‘Buy’ rating and $14 price target at Aegis Capital Corp., which noted that the commercial potential of the company’s Olinvo is “under-appreciated.” Olinvo differs from existing active drugs indicated for post-operative pain management by its mechanism of action, and it could be the first in a new class of molecules to receive FDA approval. The Aegis analyst noted that phase 3 read-outs demonstrated efficacy near the equivalent of morphine, as well as with improved side effect profiles, especially for respiratory depression and GI side effects. Aegis also estimated that Olinvo could generate $300 million in peak annual revenue.
For more information, visit www.trevena.com
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The company has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734 for pain. The company maintains an early stage portfolio of drug discovery programs.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
